Comparison
NMN vs Vinpocetine
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Vinpocetine
Semi-synthetic derivative of vincamine from periwinkle. Increases cerebral blood flow.
| Field | NMN | Vinpocetine |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 5–30mg |
| Half-life | — | 2h |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USBanned |
| PubMed refs | 600 | 600 |
The comparison in plain English
Auto-generated from dataNMN and Vinpocetine are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Vinpocetine Semi-synthetic derivative of vincamine from periwinkle.
Bottom line
NMN (evidence B, safety 5/5) matches the evidence base of Vinpocetine (evidence B, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Vinpocetine if
Vinpocetine is the better fit when your goal aligns with its mechanism (Inhibits phosphodiesterase 1 (PDE1), increasing intracellular cGMP and producing vasodilation specifically in cerebral arterioles) and the dose range (5–30mg) suits your protocol. Half-life is 2h.